INT316114

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 10
Disease Relevance 2.95
Pain Relevance 0.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

protein modification process (SAE1) nucleus (SAE1) ligase activity (SAE1)
Anatomy Link Frequency
Spike 1
arms 1
SAE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 22 68.00 Quite High
tolerance 8 63.60 Quite High
alcohol 13 52.32 Quite High
Potency 8 23.60 Low Low
anesthesia 21 5.00 Very Low Very Low Very Low
Arthritis 16 5.00 Very Low Very Low Very Low
Pain 13 5.00 Very Low Very Low Very Low
headache 12 5.00 Very Low Very Low Very Low
aspirin 8 5.00 Very Low Very Low Very Low
Electroencephalography 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Encephalopathy 36 100.00 Very High Very High Very High
Death 3 98.72 Very High Very High Very High
Apoptosis 6 98.28 Very High Very High Very High
Crystal Associated Disease 304 98.16 Very High Very High Very High
Stress 10 97.72 Very High Very High Very High
Hypertension 8 84.28 Quite High
Obesity 8 83.36 Quite High
Disease 45 82.28 Quite High
Infection 6 81.04 Quite High
Brain Injury 4 80.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For analysis of the SUA, spike sorting was performed offline using the Offline Spike Sorter (Plexon, Inc., Dallas TX), primarily through manual isolation of spike clusters in two or three dimensional feature spaces.


Gene_expression (analysis) of SUA in Spike
1) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3006173 Disease Relevance 0 Pain Relevance 0
This result may be accounted for in part by the fact that there were fewer SUA available than LFP channels.
Gene_expression (available) of SUA
2) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3006173 Disease Relevance 0 Pain Relevance 0
With SUA data, we performed two types of analyses: one using the same CSP+ECOC algorithm as described above, and one using the regularized linear discriminant analysis (rLDA), which was shown to provide better results than other methods, such as the population vector and multivariate Gaussian modeling approaches [14].
Gene_expression (data) of SUA
3) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3006173 Disease Relevance 0 Pain Relevance 0
The results show that decoding accuracy using LFP was generally slightly better than using SUA for both subjects in both sessions.
Gene_expression (using) of SUA
4) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3006173 Disease Relevance 0 Pain Relevance 0
SUA and LFP decoding
Gene_expression (decoding) of SUA
5) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3006173 Disease Relevance 0 Pain Relevance 0
There has been a dearth of primary clinical outcomes (gout flares, number or size of tophi) in this first wave of febuxostat studies, as it is expected that the marked SUA-lowering effect translates into clinical improvement in real practice.
Gene_expression (marked) of SUA associated with crystal associated disease
6) Confidence 0.13 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.50 Pain Relevance 0
Becker et al52 analyzed patients treated with febuxostat in the FACT and APEX studies trying to clarify the relationship between postbaseline SUA, a measure of the amount of SUA reduction after initiation of therapy, and the risk of gout flare.
Gene_expression (reduction) of SUA associated with crystal associated disease
7) Confidence 0.13 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.27 Pain Relevance 0
Two interim analyses have been published in abstract form, and report that continuous reduction of SUA to levels of 6.0 mg/dL or less lead to significant clinical benefits, and that a larger proportion of patients receiving allopurinol treatment compared with febuxostat 80 and 120 mg/day failed to achieve this goal.54,55 Finally, abstracts from two Japanese phase III studies reported that febuxostat 20 and 40 mg/day reduced SUA in a dose-dependent manner compared with placebo in 103 patients56 and that febuxostat 40 mg/day was more effective in reducing SUA than allopurinol 100 mg twice a day in 256 patients.57
Gene_expression (reducing) of SUA
8) Confidence 0.13 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.07 Pain Relevance 0.03
Significantly greater proportions of patients in all the febuxostat arms achieved the primary study endpoint of having the last three SUA levels measured at ?
Gene_expression (levels) of SUA in arms
9) Confidence 0.13 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.65 Pain Relevance 0.03
However, anticipating insulin effects on SAE is impossible due to the complexity of cerebral glucose metabolism and the high variability in glucose levels between patients.
Gene_expression (effects) of SAE associated with encephalopathy
10) Confidence 0.10 Published 2010 Journal Crit Care Section Body Doc Link PMC2887172 Disease Relevance 1.46 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox